Skip to main content

Table 2 Association analysis between clinicopathologic characteristics and chemosensitivity

From: Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients

Proliferation rate (%)

Gemcitabine

P

Oxaliplatin

P

5-Fluorouracil

P

Nab-paclitaxel

P

Irinotecan

P

Tumor size, cm

 < 4

65.3 ± 11.5

0.316

72.2 ± 27.9

0.814

66.5 ± 30.0

0.684

84.8 ± 28.5

0.257

71.0 ± 26.4

0.049

 ≥ 4

26.8 ± 88.6

67.3 ± 40.2

72.8 ± 21.7

35.0 ± 97.4

15.0 ± 51.9

Tumor differentiation

 Well and moderate

38.5 ± 78.2

0.699

55.0 ± 28.7

0.127

61.7 ± 24.6

0.292

35.3 ± 67.5

0.264

31.7 ± 46.8

0.449

 Poor

53.7 ± 51.2

84.5 ± 32.6

77.7 ± 25.2

84.5 ± 76.1

54.3 ± 52.7

Nerve invasion

 No

10.3 ± 72.1

0.044

74.8 ± 26.8

0.618

71.2 ± 30.2

0.848

82.7 ± 94.2

0.303

37.2 ± 56.5

0.700

 Yes

81.8 ± 24.8

64.7 ± 40.4

68.2 ± 21.9

37.2 ± 40.9

48.8 ± 44.8

Lymph node metastasis

 No

30.2 ± 85.7

0.491

55.4 ± 34.3

0.219

69.8 ± 34.1

0.989

21.4 ± 66.3

0.128

7.4 ± 38.5

0.024

 Yes

57.4 ± 46.3

80.0 ± 30.5

69.6 ± 19.7

87.4 ± 69.1

68.4 ± 40.0

TNM stage

 I–IIIA

18.3 ± 94.0

0.305

61.0 ± 36.9

0.543

64.0 ± 36.4

0.606

13.3 ± 73.6

0.122

− 7.5 ± 22.2

0.004

 IIIB–IV

60.0 ± 43.5

74.1 ± 32.7

72.5 ± 20.0

83.3 ± 65.1

68.3 ± 37.0

  1. P values were calculated by unpaired t-test (2-sided)